In this single-center registry, patients who underwent ambulatory PCI had no worse outcomes than those who stayed at least one night, at high and low ACEF scores. Background: The aim of this study was to evaluate the frequency, predictors and the clinical outcome of stent thrombosis after DES implantation and bare metal stent (BMS) implantation in Asian races. Methods: A total of 14,577 consecutive patients who underwent successful DES implantation (8,809 patients, 62% of the lesion with Sirolimus-eluting stent: SES, 38% of the lesion with Paclitaxel-eluting stent: PES) and BMS implantation (5,768 patients) were included in this study. We evaluate the frequency, predictor of stent thrombosis. Results: At a mean follow-up of 78.5Ϯ29.9 months in DES and 81.8Ϯ26.4 months in BMS. The cumulative incidence of stent thrombosis were subacute stent thrombosis (SAT): 0.5% with DES and 0.6% with BMS, late stent thrombosis (LAST): 0.18% with DES and 0.1% with BMS, very late stent thrombosis (VLAST): 0.18% per year with DES and no BMS. Independent predictors of stent thrombosis are bifurcation lesion (ORϭ1.90, 95% CI: 1.83 to 24.24, pϭ0.01) and ejection fraction (ORϭ0.90, 95% CI: 0.86 to 0.94, pϭ0.03). Only 0.2 % of the patients were died because of the myocardial infarction after stent thrombosis in both groups. Conclusions: The incidence of stent thrombosis in Asian races is relatively low (0.5 % with DES and 0.6% with BMS of SAT, 0.18% increase per year with DES of late stent thrombosis) at mean follow-up to 7 years. Particular attention will need to be directed to this complication when the patients have bifurcation lesions or low ejection fraction. Methods: 210 patients were randomized 2:1 either to the DESyne CSS loaded with 5mcg per mm of stent length of Novolimus, a sirolimus metabolite, eluted via a durable methacrylate polymer, or to the Endeavor CSS loaded with 10mcg per mm of stent length of Zotarolimus eluted via a durable phosphoryl choline polymer. All patients were analyzed for the primary endpoint of late lumen loss (LLL) assessed by QCA at 9 months. All patients also underwent evaluation for secondary endpoints which included a Device-orientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization (TLR); clinically-indicated Target Vessel Revascularization (TVR); and stent thrombosis all evaluated at 1, 6, 9, and 12 months and annually through 5 years. Stents were also assessed for angiographic endpoints at 9 months including: in-stent and in-segment LLL. A subset of patients underwent IVUS evaluation including percent neointimal obstruction at 9 months. The study met the non-inferiority endpoint and also demonstrated superiority of the DESyne CSS as compared to control. Results: Table 1 summarizes 9-month angiographic and IVUS results and clinical results through 2 years which trend lower for the DESyne stent. 
Kobe University Graduate School of Medicine, Hyogo, 13 Thoraxcenter, Erasmus Medical center, Rotterdam, Netherlands Background: Aims: To evaluate safety and effectiveness of the Elixir DESyneTM Novolimus-Eluting Coronary Stent System (CSS) compared to the Endeavor Zotarolimus-Eluting CSS through assessment of clinical, angiographic, and IVUS endpoints. Methods: 210 patients were randomized 2:1 either to the DESyne CSS loaded with 5mcg per mm of stent length of Novolimus, a sirolimus metabolite, eluted via a durable methacrylate polymer, or to the Endeavor CSS loaded with 10mcg per mm of stent length of Zotarolimus eluted via a durable phosphoryl choline polymer. All patients were analyzed for the primary endpoint of late lumen loss (LLL) assessed by QCA at 9 months. All patients also underwent evaluation for secondary endpoints which included a Device-orientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization (TLR); clinically-indicated Target Vessel Revascularization (TVR); and stent thrombosis all evaluated at 1, 6, 9, and 12 months and annually through 5 years. Stents were also assessed for angiographic endpoints at 9 months including: in-stent and in-segment LLL. A subset of patients underwent IVUS evaluation including percent neointimal obstruction at 9 months. The study met the non-inferiority endpoint and also demonstrated superiority of the DESyne CSS as compared to control. Results: Table 1 summarizes 9-month angiographic and IVUS results and clinical results through 2 years which trend lower for the DESyne stent. The majority of patients undergoing stenting procedures were also diagnosed with hypertension (75-85%) with revascularization rates higher among this population than primary procedures. Over 60% of patients undergoing a DES stenting procedure (primary or revascularization) are implanted with one stent while 27% are implanted with two stents and less than 10% receive 3 or more stents. The same trend was observed for patients undergoing primary or revascularization BMS procedures. Ten-year Kaplan Meir mortality rates were also assessed among the DES and BMS patient populations. The average hospitalization charges for primary DES procedures was $64,000, whereas the average charges for BMS procedures were $10,000-23,000 lower than DES procedures. Conclusions: Temporal trends showed that concerns about late-stent thrombosis with use of DES led to a sharp decline in utilization. Analysis of mortality and revascularization following BMS and DES procedures provided information about the comparative safety and effectiveness of these procedures. Background: Acute cerebrovascular episode (CVA) following percutaneous coronary intervention (PCI) is a rare but devastating complication. We sought to determine the incidence and predictors of stroke following PCI in United States. Methods: The Nationwide Inpatient Sample (NIS) database was used to identify all patients who developed acute CVA following PCI between January and December 2009. Risk adjusted logistic regression was performed to identify independent predictors of acute stroke following PCI. Results: Of the 444,326 patients who underwent PCI, 437 (0.1%) acute strokes were identified. The in-hospital mortality rate in patients who developed stroke was significantly higher than in control group (2.3% vs. 0.6%, p Ͻ 0.01). Independent predictors of stroke following PCI were history of drug abuse (OR 7.2, 95% CI {4.5 -11.4}, p Ͻ0.01), valvular heart disease (OR 3.2, 95% CI {1.6 -6.7}, p Ͻ 0.01), age Ͼ65 (OR 2.9, 95% CI {2.3 -3.7}, p Ͻ0.01), diabetes with complications (OR 2.0, 95% CI {1.4 -2.7}, p Ͻ 0.01), female sex (OR 1.6, 95% CI {1.3 -2.0}, p Ͻ 0.01), history of coronary artery bypass grafting (OR 1.6, 95% CI {1.2 -2.1}, p Ͻ 0.01) and history of myocardial infarction (OR 1.5, 95% CI {1.2 -1.9}, p Ͻ 0.01).
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Conclusions:
In this observational study we found that risk of stroke following PCI is low, whereas the in-hospital mortality associated with this complication is high. The independent predictors of stroke complication include history of drug abuse, valvular heart disease, advanced age, diabetes with complications, prior CABG or MI. Background: Endothelial dysfunction of coronary artery has been reported in patients following the first generation drug eluting stent (DES) implantation. However, the incidence and clinical relevance of the second generation DES-induced endothelial dysfunction have not been fully investigated. The aim of this study was to estimate the incidence and clinical relevance of endothelial dysfunction after implantation of everolimus-eluting stent (EES). Methods: Since June 2006 until August 2011, the present study enrolled 757 patients who were treated solely with DES for de novo lesions, from our prospective institutional database. The patients (279 patients with sirolimus-eluting stent (SES), 210 patients with paclitaxel-eluting stent (PES), and 268 patients with EES) were requested to undergo 8-month follow-up angiography. Endothelial function was evaluated, in case the patients had angina symptom and/or positive exercise electrocardiogram test without in-stent restenosis at the time of follow-up angiography by infusion of incremental acetylcholine and isosorbide dinitrate into the coronary artery. Vascular responses were quantitatively measured in segments proximal, distal, proximal reference and distal reference to DES location. Endothelial dysfunction was defined as abnormal vasoconstriction of Ն 3% mean vessel diameter changes. Results: Follow-up angiography was performed in 624 patients (82.4%)of the 757 patients. There were 59 patients (7.8%) who met the inclusion criteria for endothelial function test, 25 patients (8.9%) with SES, 15 patients (7.1%) with PES, 19 patients (7.1%) with EES. In all the 3 groups significant vasoconstriction after acetylcholine infusion was observed in segments distal to stents compared to baseline(pϽ0.05). Vasodilation in response to isosorbide dinitrate infusion was also observed. Endothelial dysfunction was quantitatively assessed in all the 59 patients at distal segments to DES. No significant differences were observed in percent diameter changes from baseline among the groups. Conclusions: Clinically relevant endothelial dysfunction following EES implantation seems to be present in approximately 7%, which is similar to the first generation DES implantation.
TCT-661
TCT-662
One 
